Hepion Pharmaceuticals Inc. has approved a new employment agreement for Dr. Kaouthar Lbiati, appointing her as Chief Executive Officer effective January 8, 2026. Under the agreement, Dr. Lbiati will receive an annual base salary of $350,000, with $50,000 of this amount deferred and payable upon certain conditions such as successful equity financing, termination, or a change of control. She is also eligible for an annual discretionary cash bonus targeted at 35% of her base salary, based on the achievement of goals set by the Board. In the event of a change of control where the company’s enterprise value reaches at least $5 million, Dr. Lbiati will accrue a bonus equal to 3% of the enterprise value. The agreement provides for severance benefits, including six months of base salary, pro-rata bonus, continued benefits, and accelerated vesting of equity awards, under certain termination scenarios such as termination without cause or resignation for good reason, particularly in relation to change of control events.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hepion Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-002428), on January 15, 2026, and is solely responsible for the information contained therein.